First Author: A.Kogiantis UK
Co Author(s): F. Barampouti M. Karampelas 0 0 0 0 0 0 0 0 0
Back to previous
The advent of anti-vascular endothelial factor agents has revolutionised treatment of the wet form of age related macular degeneration (AMD). However, data from randomised trials have shown that the response to ranibizumab varies amongst patients. The aim of our study is to describe the treatment response to aflibercept in patients with wet AMD that showed incomplete response after multiple injections of ranibizumab.
Medical Retina Department, Watford General Hospital, London, UK
This was a retrospective study including patients that were switched from ranibizumab to aflibercept over a period of 1 year. Indications for switching included persistent intraretinal and subretinal fluid as well as enlargement of pigment epithelial detachments. Visual acuity (VA) and central subfield retinal thickness on optical coherence tomography (CRT) scans were collected.
Ten eyes of 10 patients were included. All eyes had at least 7 previous ranibizumab injections. Mean VA prior to switching to aflibercept was 0.47 logMAR, and following the first aflibercept injection was 0.3 logMAR. OCT improved in 7 out of 10 patients after their first aflibercept injection.
According to our preliminary results, aflibercept appears to be effective in patients with neovascular age-related macular degeneration who were resistant to previous therapy of ranibizumab.